A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast
Status: NOT_YET_RECRUITING
Study type: OBSERVATIONAL
Conditions: The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
Interventions: OTHER: Verzenios
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Eli Lilly and Company